Nuveen
XENE icon

Nuveen’s Xenon Pharmaceuticals XENE Stock Holding History

Nuveen’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.9M Buy
993,126
+743,090
+297% +$41.3M 0.01% 611
2026
Q1 		$14.5M Buy
250,036
+33,798
+16% +$1.56M ﹤0.01% 1323
2025
Q4 		$9.69M Sell
216,238
-8,051
-4% -$338K ﹤0.01% 1572
2025
Q3 		$9.01M Sell
224,289
-4,278
-2% -$151K ﹤0.01% 1613
2025
Q2 		$7.15M Buy
+228,567
New +$7.46M ﹤0.01% 1707
2024
Q2 		– Sell
-42,473
Closed -$1.83M – 3425
2024
Q1 		$1.83M Buy
42,473
+2,109
+5% +$97K ﹤0.01% 2443
2023
Q4 		$1.86M Sell
40,364
-1,331
-3% -$47K ﹤0.01% 2444
2023
Q3 		$1.42M Buy
41,695
+1,496
+4% +$56K ﹤0.01% 2432
2023
Q2 		$1.55M Sell
40,199
-13,108
-25% -$521K ﹤0.01% 2469
2023
Q1 		$1.91M Buy
53,307
+2,027
+4% +$74.9K ﹤0.01% 2352
2022
Q4 		$2.02M Buy
51,280
+920
+2% +$33.5K ﹤0.01% 2383
2022
Q3 		$1.82M Buy
50,360
+6,049
+14% +$217K ﹤0.01% 2443
2022
Q2 		$1.35M Sell
44,311
-5,486
-11% -$166K ﹤0.01% 2647
2022
Q1 		$1.57M Buy
49,797
+7,913
+19% +$237K ﹤0.01% 2623
2021
Q4 		$1.31M Buy
41,884
+12,586
+43% +$376K ﹤0.01% 2758
2021
Q3 		$448K Sell
29,298
-24,156
-45% -$420K ﹤0.01% 3186
2021
Q2 		$995K Buy
53,454
+35,811
+203% +$660K ﹤0.01% 3009
2021
Q1 		$316K Buy
17,643
+5,043
+40% +$85.5K ﹤0.01% 3165
2020
Q4 		$194K Buy
+12,600
New +$147K ﹤0.01% 3201

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Nuveen's XENE Position: Q2 2026 in Review

Nuveen increased its Xenon Pharmaceuticals (XENE) stake by 297% in Q2 2026, buying an estimated $41.3M and bringing the position to 993,126 shares worth $59.9M. The position accounts for 0.01% of the portfolio, ranked #611.

Nuveen first reported a position in XENE in Q4 2020 and has held it in 19 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Nuveen held 993,126 shares of Xenon Pharmaceuticals worth $59.9M as of Q2 2026.
  • Nuveen bought 743,090 Xenon Pharmaceuticals shares in Q2 2026, an estimated $41.3M.
  • Xenon Pharmaceuticals made up 0.01% of Nuveen's portfolio in Q2 2026, its #611 holding.
  • Nuveen first reported a position in Xenon Pharmaceuticals in Q4 2020 and has held it in 19 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.